NEW YORK, Dec. 3 — Gene Prot and Waters announced Monday an agreement to equip GeneProt’s new industrial-scale proteomics facility.
Waters, through its subsidiary Micromass UK, will buy a maximum of $10 million of equity securities in GeneProt. The proteomics company will in turn purchase from Micromass about $20 million in mass spectrometry machines and services. The two companies will also collaborate on product development for these instruments.
GeneProt announced in October that it was building a 100,000 square foot, 150-person proteomics facility in North Brunswick, NJ. Scheduled to be fully operational in the second quarter of 2002, the new protein sequencing and analysis center will double the company’s capacity. GeneProt says it will be the largest proteomics center in the US.
Micromass will supply a total of 45 new Micromass Q-Tof instruments to the center, 40 of which are advanced integrated Micromass CapLC Q-Tof Micro systems. They are slated to be installed by mid-2002. Although it is primarily equipped with Micromass technology, the North Brunswick center will also include six new Bruker Daltonics MALDI-TOF/TOF machines.
In September 2000, GeneProt struck a similar deal with Bruker to equip its Geneva facility. Under that arrangement, GeneProt installed 51 Bruker machines — 45 ion trap and six MALDI-TOF instruments — in exchange for an undisclosed equity investment, stocking its new Swiss proteomics facility exclusively with Bruker instruments.